AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

What's New in Cosmetic Neuromodulators

Description

The presentation discusses recent advancements in cosmetic neuromodulators, emphasizing the surge in new approvals and the evolving landscape of aesthetic treatments. Three new neuromodulators have received approval, including Letty for glabella lines, Inco for upper facial lines, and Anna for the platysma. The latter is noted for improving neck aesthetics, a concern for many patients, and has recently gained FDA approval. The session highlights a new liquid formulation of botulinum toxin, Relfedes, and presents data suggesting enhanced skin texture post-treatment. A focus is placed on the growing consumer base of millennials, their willingness to spend on aesthetic treatments, and their higher satisfaction rates compared to baby boomers. The talk also covers how social media influences patient decisions regarding neuromodulator treatments but reiterates the importance of clinic reputation. Overall, the body of work indicates a positive trajectory for neuromodulators in modifying not just visible signs of aging but also patient satisfaction and skincare quality.

View more

Conclusions

  • New neuromodulators have been approved, highlighting advancements in the field.
  • LetibotulinumtoxinA received FDA approval for glabellar lines in March 2024.
  • IncobotulinumtoxinA gained approval for upper facial lines in July 2024 and provides consistent treatment outcomes.
  • OnabotulinumtoxinA was approved for platysma prominence in October 2024, addressing common aesthetic concerns.
  • Millennials respond better to neuromodulator treatments compared to older generations, indicating demographic shifts in patient satisfaction.
  • New formulations like Relfydess showed improved skin texture outcomes after treatment with neuromodulators.
  • The ongoing growth of the neuro cosmetic market projects significant increases in the coming years, signifying rising demand.
  • Injecting neuromodulators affects not only muscle function but also contributes to enhanced skin quality.
  • Trindade de Almeida A, Romiti A, Carruthers J. The Facial Platysma and its Underappreciated role in Lower Facial Dynamics and Contour. Dermatol Surg 2017;43:1042-1049.
  • Mary B Gadarowski, Rima Ghamrawi, Sarah L Taylor, Steven R Feldman. PrabotulinumtoxinA-xvfs for the Treatment of Moderate-to-Severe Glabellar Lines. Ann Pharmacother. 2021 Mar;55(3):354-361. doi: 10.1177/1060028020943527. Epub 2020 Jul 22.
  • Patricia Ogilvie, Derek H. Jones, Rui L. Avelar, Anneke Jonker, Rose Monroe, Jean Carruthers. PrabotulinumtoxinA for Treatment of Millennials With Moderate to Severe Glabellar Lines: Post Hoc Analyses of the Phase III Clinical Study Data. Dermatol Surg. 2022;48(6):664-669.
  • Ya-Nin Nokdhes, Panwadee Thongjaroensirikul, Thanya Techapichetvanich. Efficacy and Safety of LetibotulinumtoxinA in the Treatment of Moderate and Severe Glabellar Lines in Females 35 to 50 Years of Age: Post Hoc Analyses of the Phase 3 Clinical Study Data. Dermatol Ther (Heidelb) (2024) 14:1315-1325. https://doi.org/10.1007/s13555-024-01177-1